BMO Upgrades Cineplex Price Target To $7.00, Rating To Market Perform

On Friday, Cineplex Inc (TSX: CGX) reported their third quarter results. Cineplex’s revenue was $61 million compared to 2019 third quarter’s revenue of $418.4 million, and while the reported loss per share came in at $1.91. They also announced that their financial covenant suspension will be extended until the second quarter of 2021 and that there was $460 million outstanding under credit facilities.

BMO Capital Markets released a note today, increasing its 12-month price target and rating on Cineplex. They now have a C$7 price target and market perform ratings, up from C$6 and underperform. Tim Casey, BMO’s analyst, comments, “encouraging developments regarding vaccines provide incremental optimism that consumers will return to theatres next year.” Although he accepts that a “return to normal” scenario is a much longer-term thought, the excellent vaccine data reduced what he calls a “value-destroying liquidity event.”

Casey expects financials will remain weak in the fourth quarter, “given current pandemic realities regarding closures in much of Canada and a lack of new product from Hollywood,” and that everything, “hinges on a recovery from the pandemic,” in 2021.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Casey calls the new credit agreement with lenders a favorable scenario and believes Cineplex must generate between C$27 and C$30 million in annualized EBITDA in 2021 to clear the covenant test next year. He adds, “A liquidity test of a minimum $100mm through 1/31/21 seems to be a much easier bar to reach.” He forecasts that in the second quarter of 2021, cash burn improves to being flat while the business operates at 50% revenue compared to the same quarter in 2019.

He adds that they expect the industry to recover to a sustainable level that is lower than pre-COVID levels and says, “Longer-term challenges remain.” He adds that he believes COVID just accelerated the industry’s headwinds from the demand and supply side.

With the price target and rating increase, BMO raised its 2020 and 2021 estimates, which can be seen below.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

CloudMD Gets Price Target Cut By Canaccord Genuity

On Monday CloudMD Software & Services Inc. (TSXV: DOC) reported its fourth quarter results for...

Wednesday, May 4, 2022, 03:06:00 PM

Canaccord Lowers Else Nutrition Estimates After Disappointing Quarter

This past week, Else Nutrition (CSE: BABY) reported their second quarter financial results. The company...

Friday, September 3, 2021, 11:11:00 AM

Cybin: Canaccord Bumps Price Target To US$7.00

Cybin Inc (NEO: CYBN) last month had a long month of news reports, the first...

Thursday, September 2, 2021, 11:16:00 AM

Valens Sees Canaccord Cut Price Target After Investor Day

On February 7th, The Valens Company (TSX: VLNS) held its 2022 investor day. The company...

Friday, February 11, 2022, 02:54:00 PM

Tesla: Canaccord Doubles Price Target To $1,071

On Monday, one of the more bearish Tesla Inc. (NASDAQ: TSLA) analysts flipped bullish, and...

Tuesday, April 13, 2021, 11:41:00 AM